{"doi":"10.1016/j.ejca.2021.02.011","title":"Prolonged SARS-CoV-2 viral shedding in patients with solid tumours and associated factors","abstract":null,"journal":"European Journal of Cancer","year":2021,"id":606541,"datarank":0.40620753016533157,"base_score":2.70805020110221,"endowment":2.70805020110221,"self_citation_contribution":0.40620753016533157,"citation_network_contribution":0.0,"self_endowment_contribution":0.40620753016533157,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":14,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":430751,"name":"Pedro Gullón","orcid":"0000-0002-7641-1514","position":1,"is_corresponding":false},{"id":1557151,"name":"Berta Obispo","orcid":null,"position":2,"is_corresponding":false},{"id":1557152,"name":"Gloria Serrano","orcid":null,"position":3,"is_corresponding":false},{"id":1557153,"name":"Miguel Á. Lara","orcid":"0000-0002-1737-3722","position":4,"is_corresponding":false},{"id":1557150,"name":"Jacobo Rogado","orcid":"0000-0002-9795-8762","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Prolonged SARS-CoV-2 viral shedding in patients with solid tumours and associated factors","abstract":null,"is_dataset_classified":null,"base_score":0.0,"endowment":0.0,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"33735810","pmcid":"PMC7901370","openalex_id":null,"authors":[],"funders":[],"total_grants":0,"fwci":null,"citation_percentile":null,"influential_citations":0,"citation_trend":[],"oa_status":"bronze","license":"https://www.elsevier.com/legal/tdmrep-license","oa_locations":[{"url":"http://www.ejcancer.com/article/S0959804921000940/pdf","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S0959804921000940?httpAccept=text/xml","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S0959804921000940?httpAccept=text/plain","host_type":"publisher"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/7901370","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC7901370","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC7901370?pdf=render","host_type":"Europe_PMC"}],"fields_of_study":[],"mesh_terms":["Humans","Neoplasms","Breast Neoplasms","Lung Neoplasms","Ritonavir","Hydroxychloroquine","Dexamethasone","Alanine","Adenosine Monophosphate","Antineoplastic Agents","Drug Combinations","Glucocorticoids","Antiviral Agents","Immunotherapy","Immunization, Passive","Proportional Hazards Models","Risk Factors","Follow-Up Studies","Virus Shedding","Time Factors","Aged","Spain","Female","Male","Molecular Targeted Therapy","Lopinavir","COVID-19","SARS-CoV-2","COVID-19 Serological Testing","COVID-19 Nucleic Acid Testing","Latent Infection","COVID-19 Serotherapy","COVID-19 Drug Treatment"],"keywords":[],"sdg_mappings":[],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-30T04:44:52.235316Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}